Skip to main content
IlluminaIn development

Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology

Source: Autobound Signal API · 107 signals tracked for Illumina · updated

Get Illumina's live signals in Claude or ChatGPT, or by API

AskWhat changed at Illumina this week? Use Autobound signals for illumina.com.

What happened

Illumina announced an early access program for its ultrasensitive duplex sequencing workflow designed for molecular residual disease research, with kits expected to ship in the first quarter of 2027.

Source

Article excerpt

Early access program launches to support ultrasensitive research into molecular residual disease and tumor evolution. New chemistry is optimized for highest possible accuracy, with reproducible detection of ctDNA at 2.5 parts per million levels with low sample input (10 nanograms) in representative studies SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced an expansion of its molecular residual disease (MRD) research portfolio with an early access program for an ultrasensitive sequencing workflow. Designed to detect trace amounts of circulating tumor DNA (ctDNA) in plasma samples, the workflow's duplex chemistry analyzes both strands of a DNA molecule to increase confidence in detection. It combines the latest sequencing and software advances from the NovaSeq X platform and DRAGEN bioinformatics software to support longitudinal, whole-genome studies of MRD. "Researchers need effective ways to find the faintest traces of tumor DNA - signals that can be especially difficult to detect in early-stage, low-shedding, or low-mutation-burden tumors," said Cande Rogert, vice president, Global Head of Advanced Science, Illumina. "This early access technology is an important step toward helping researchers explore those challenging settings with greater sensitivity and generate evidence that can advance MRD research." The new duplex sequencing...

Keep reading with a free account

The rest of this article, and every signal for Illumina, is in your free account.

Extracted from this sentence

Kits for the early access program are expected to ship in the first quarter of 2027.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
duplex sequencing workflow
Location
San Diego, California, United States

The full record

From the Signal API record

Details

Ticker
NASDAQ:ILMN

Topics and mentions

Product tags

  • medical
  • general technology
  • future tech

Extraction

Confidence
95%
Detected
Nov 9, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for Illumina and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Illumina this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/9dcf9d1f-ace2-0040-b188-a35141e51f16 returns this record as JSON. POST /v1/companies/enrich returns every signal for illumina.com.

{
  "signal_id": "9dcf9d1f-ace2-0040-b188-a35141e51f16",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-09T14:15:00+00:00",
  "company": {
    "name": "Illumina",
    "domain": "illumina.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/illumina-advances-mrd-research-portfolio-with-ultrasensitive-duplex-sequencing-technology-302932912.html",
    "title": "Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology",
    "ticker": "NASDAQ:ILMN",
    "excerpt": "Early access program launches to support ultrasensitive research into molecular residual disease and tumor evolution. New chemistry is optimized for highest possible accuracy, with reproducible detection of ctDNA at 2.5 parts per million levels with low sample input (10 nanograms) in representative studies SAN DIEGO , Nov. 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced an expansion of its molecular residual disease (MRD) research portfolio with an early access program for an ultrasensitive sequencing workflow. Designed to detect trace amounts of circulating tumor DNA (ctDNA) in plasma samples, the workflow's duplex chemistry analyzes both strands of a DNA molecule to increase confidence in detection. It combines the latest sequencing and software advances from the NovaSeq X platform and DRAGEN bioinformatics software to support longitudinal, whole-genome studies of MRD. \"Researchers need effective ways to find the faintest traces of tumor DNA - signals that can be especially difficult to detect in early-stage, low-shedding, or low-mutation-burden tumors,\" said Cande Rogert, vice president, Global Head of Advanced Science, Illumina. \"This early access technology is an important step toward helping researchers explore those challenging settings with greater sensitivity and generate evidence that can advance MRD research.\" The new duplex sequencing...",
    "product": "duplex sequencing workflow",
    "summary": "Illumina announced an early access program for its ultrasensitive duplex sequencing workflow designed for molecular residual disease research, with kits expected to ship in the first quarter of 2027.",
    "location": "San Diego, California, United States",
    "planning": true,
    "image_url": "https://mmx.prnewswire.com/media/MS2029728/AMP_Verona-Social-Animation_v5_10-27-26.mp4?id=OA3064458&p=thumbnail",
    "confidence": 0.95,
    "product_data": {
      "name": "duplex sequencing workflow",
      "full_text": "ultrasensitive duplex sequencing workflow",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology",
      "future_tech"
    ],
    "published_at": "2026-11-09T14:15:00Z",
    "location_data": [
      {
        "city": "San Diego",
        "state": "California",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Kits for the early access program are expected to ship in the first quarter of 2027."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.